"In this trial of difficult-to-treat patients, 82% were completely or partially healed with an average reduction in skin ulcer area of 56%. Given that these 44 patients had on average not responded to 3 years of expert care, these are superb results."
Superb results indeed that would not have gone un-noticed!
Its a matter of when, not if, a takeover is launched, and this announcement today facilitates that perfectly IMO, as has been alluded to in the ann:
"b) Enhanced position in merger / strategic alliance negotiations with pharma due to fully integrated
commercialisation infrastructure and lack of contractual restraints"
FTT Price at posting:
7.1¢ Sentiment: Buy Disclosure: Held